STOCK TITAN

[Form 4] Bolt Biotherapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Bolt Biotherapeutics (BOLT) reported an insider equity award. The Chief Operating Officer received 30,000 restricted stock units for no consideration on 10/22/2025. Each RSU represents the right to receive one share of common stock at settlement.

The award will vest in full on September 15, 2026, assuming continued employment through that date. Following the reported transaction, the officer beneficially owned 38,918 shares of common stock, held directly.

Bolt Biotherapeutics (BOLT) ha comunicato un premio azionario per insider. Il Chief Operating Officer ha ricevuto 30.000 unità azionarie vincolate senza alcun pagamento il 22/10/2025. Ogni RSU rappresenta il diritto di ricevere una azione ordinaria al momento della liquidazione.

Il premio maturerà integralmente il 15 settembre 2026, a condizione di impiego continuo fino a tale data. Dopo la transazione riportata, l’ufficiale possedeva direttamente 38.918 azioni ordinarie.

Bolt Biotherapeutics (BOLT) informó sobre una compensación de acciones para insiders. El Director de Operaciones recibió 30,000 unidades de acciones restringidas sin contraprestación el 22/10/2025. Cada RSU representa el derecho a recibir una acción ordinaria en la liquidación.

La compensación vencerá por completo el 15 de septiembre de 2026, suponiendo empleo continuo hasta esa fecha. Tras la transacción reportada, el oficial poseía beneficamente 38,918 acciones ordinarias, mantenidas directamente.

Bolt Biotherapeutics (BOLT) 내부자 주식 보상에 대해 보고했습니다. 최고운영책임자(COO)가 30,000개의 제한주식단위를 대가 없이 받았으며 날짜는 2025년 10월 22일입니다. 각 RSU는 규정일에 일반주식 1주를 받을 권리를 나타냅니다.

이 보상은 2026년 9월 15일에 전액 가속 vesting되며, 그 날짜까지 계속 고용되었음을 전제로 합니다. 보고된 거래 후, 그 임원은 직접 보유한 일반주식 38,918주를 보유했습니다.

Bolt Biotherapeutics (BOLT) a déclaré une attribution d'actions pour initiés. Le directeur des opérations a reçu 30 000 unités d'actions restreintes sans contrepartie le 22/10/2025. Chaque RSU donne le droit de recevoir une action ordinaire lors du règlement.

L'attribution vestira intégralement le 15 septembre 2026, sous réserve de l'emploi continu jusqu'à cette date. Suite à la transaction rapportée, le cadre détenait effectivement 38 918 actions ordinaires, détenues directement.

Bolt Biotherapeutics (BOLT) meldete eine Insider-Aktienzuteilung. Der Chief Operating Officer erhielt 30.000 Restricted Stock Units ohne Gegenleistung am 22.10.2025. Jede RSU berechtigt dazu, eine Stammaktie bei Erfüllung zu erhalten.

Die Zuteilung wird am 15. September 2026 vollständig vestet, vorausgesetzt, dass das Arbeitsverhältnis bis zu diesem Datum fortbesteht. Nach dem gemeldeten Vorgang hielt der Offizielle direkt 38.918 Stammaktien.

Bolt Biotherapeutics (BOLT) أبلغت عن جائزة أسهم داخلية. تلقى مدير التشغيل التنفيذي 30,000 وحدة أسهم مقيدة بدون مقابل في 22/10/2025. تمثل كل RSU الحق في الحصول على سهم عادي عند التسوية.

ستكتمل منح التملك (الفيستنغ) بالكامل في 15 سبتمبر 2026، بشرط استمرار العمل حتى ذلك التاريخ. وبعد المعاملة المذكورة، امتلك المسؤول بشكل مستفيد 38,918 سهمًا عاديًا، مملوكة مباشرة.

Positive
  • None.
Negative
  • None.

Bolt Biotherapeutics (BOLT) ha comunicato un premio azionario per insider. Il Chief Operating Officer ha ricevuto 30.000 unità azionarie vincolate senza alcun pagamento il 22/10/2025. Ogni RSU rappresenta il diritto di ricevere una azione ordinaria al momento della liquidazione.

Il premio maturerà integralmente il 15 settembre 2026, a condizione di impiego continuo fino a tale data. Dopo la transazione riportata, l’ufficiale possedeva direttamente 38.918 azioni ordinarie.

Bolt Biotherapeutics (BOLT) informó sobre una compensación de acciones para insiders. El Director de Operaciones recibió 30,000 unidades de acciones restringidas sin contraprestación el 22/10/2025. Cada RSU representa el derecho a recibir una acción ordinaria en la liquidación.

La compensación vencerá por completo el 15 de septiembre de 2026, suponiendo empleo continuo hasta esa fecha. Tras la transacción reportada, el oficial poseía beneficamente 38,918 acciones ordinarias, mantenidas directamente.

Bolt Biotherapeutics (BOLT) 내부자 주식 보상에 대해 보고했습니다. 최고운영책임자(COO)가 30,000개의 제한주식단위를 대가 없이 받았으며 날짜는 2025년 10월 22일입니다. 각 RSU는 규정일에 일반주식 1주를 받을 권리를 나타냅니다.

이 보상은 2026년 9월 15일에 전액 가속 vesting되며, 그 날짜까지 계속 고용되었음을 전제로 합니다. 보고된 거래 후, 그 임원은 직접 보유한 일반주식 38,918주를 보유했습니다.

Bolt Biotherapeutics (BOLT) a déclaré une attribution d'actions pour initiés. Le directeur des opérations a reçu 30 000 unités d'actions restreintes sans contrepartie le 22/10/2025. Chaque RSU donne le droit de recevoir une action ordinaire lors du règlement.

L'attribution vestira intégralement le 15 septembre 2026, sous réserve de l'emploi continu jusqu'à cette date. Suite à la transaction rapportée, le cadre détenait effectivement 38 918 actions ordinaires, détenues directement.

Bolt Biotherapeutics (BOLT) meldete eine Insider-Aktienzuteilung. Der Chief Operating Officer erhielt 30.000 Restricted Stock Units ohne Gegenleistung am 22.10.2025. Jede RSU berechtigt dazu, eine Stammaktie bei Erfüllung zu erhalten.

Die Zuteilung wird am 15. September 2026 vollständig vestet, vorausgesetzt, dass das Arbeitsverhältnis bis zu diesem Datum fortbesteht. Nach dem gemeldeten Vorgang hielt der Offizielle direkt 38.918 Stammaktien.

Bolt Biotherapeutics (BOLT) أبلغت عن جائزة أسهم داخلية. تلقى مدير التشغيل التنفيذي 30,000 وحدة أسهم مقيدة بدون مقابل في 22/10/2025. تمثل كل RSU الحق في الحصول على سهم عادي عند التسوية.

ستكتمل منح التملك (الفيستنغ) بالكامل في 15 سبتمبر 2026، بشرط استمرار العمل حتى ذلك التاريخ. وبعد المعاملة المذكورة، امتلك المسؤول بشكل مستفيد 38,918 سهمًا عاديًا، مملوكة مباشرة.

Bolt Biotherapeutics (BOLT) 公布了一项内部人股票奖励。首席运营官在2025/10/22收到 30,000 股受限股票单位,无需对价。每个 RSU 代表在结算时取得一股普通股的权利。

该奖励将在2026/9/15完全归属,前提是该日期前仍在职。报告交易后,该官员实际拥有 38,918股普通股,直接持有。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Yonehiro Grant

(Last) (First) (Middle)
C/O BOLT BIOTHERAPEUTICS, INC.
900 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025(1) (2) A 30,000 A $0(1) 38,918 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
2. The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date.
/s/ William P. Quinn, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Bolt Biotherapeutics, Inc.

NASDAQ:BOLT

BOLT Rankings

BOLT Latest News

BOLT Latest SEC Filings

BOLT Stock Data

11.06M
1.88M
2.26%
44.61%
4.06%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY